X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ISA106
Therapeutic Area: Infections and Infectious Diseases Product Name: ISA106
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2021
Details:
ISA106 is an immunotherapy agent that is intended to treat patients with SARS-CoV2 infections, and prevent progressive pneumonia and further complications – thereby avoiding admission to hospital and ICU.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Aim ImmunoTech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 29, 2021
Details:
CHDR, will conduct and manage the proposed clinical study, titled “A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen (Poly I:Poly C12U) in Healthy Subjects.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AKS-452
Therapeutic Area: Infections and Infectious Diseases Product Name: AKS-452
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Akston Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 01, 2020
Details:
TRACER will will provide regulatory services, oversight of local manufacturing contractors as well as Phase 1 Study preparation and clinical site management for Akston Biosciences' Phase 1 clinical testing in of its lead COVID-19 vaccine candidate, AKS-452.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HP163
Therapeutic Area: Infections and Infectious Diseases Product Name: HP163
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2020
Details:
A recent publication in Nature Neuroscience reported that Hercules’ AhR inhibitor HP163 reduces viral replication in animals infected with Zika-virus and reduced microencephaly.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
